As of February 1st, CBD has been officially classified as a dangerous drug and is now subject to regulation under Hong Kong's Dangerous Drugs Ordinance (Chapter 134).
Following this, the Hong Kong police force and customs department will make every effort to crackdown on drug-related offenses involving CBD.
After the law takes effect, those trafficking and illegally manufacturing CBD and its products can be sentenced to life imprisonment and fined up to HKD 5 million (approximately RMB 4.3 million). Those who possess or use the substance in violation of the Dangerous Drugs Ordinance can be sentenced to seven years in prison and fined up to HKD 1 million (approximately RMB 860,000).
The Hong Kong government previously arranged for a disposal collection of items containing CBD, allowing citizens to voluntarily dispose of them, and assisting those in need with large-scale disposals. As of January 29th, the government has collected approximately 77,400 items containing CBD, mostly skincare products, oral oils, and health supplements.
Reference:
Hong Kong is planning to completely ban the sale of CBD products by the end of 2022.
Starting tomorrow, regulations regarding cannabidiol (CBD) will be enforced and those who violate them will face legal consequences.
Hong Kong plans to ban the sale of CBD products entirely by the end of 2022.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
